Roche/Spark Acquisition: First Gene Therapy Deal Clears FTC With No Divestiture
FTC found Roche would not have incentive to delay or discontinue development of Spark's gene therapy for hemophilia A. Outcome shows deals can survive closer FTC scrutiny.
You may also be interested in...
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
FTC is working with Canadian and European enforcement agencies to come up with new approach to merger reviews that could look at effects on innovation and companies' past conduct. FTC to review closed mergers to see if corrective action is necessary, FTC acting chair says.
Divesting Celgene's psoriasis drug Otezla will remedy anticompetitive harm from acquisition, US Federal Trade Commission votes 3-2. Dissenting Democrat commissioners want broader review of pharma mergers.